Familial and racial determinants of tumour suppressor genes promoter hypermethylation in breast tissues from healthy women

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 B, 2010, Pages 1468-1475

  Dumitrescu, R G ^a   Marian, C ^a   Krishnan, S S ^a   Spear, S L ^a   Kallakury, B V S ^a   Perry, D J ^c   Convit, J R ^c   Seillier Moiseiwitsch, F ^a   Yang, Y ^a   Freudenheim, J L ^b   Shields, P G ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

BRCA1; Breast biology; ER CpG islands hypermethylation; Family history of cancer; P16INK4

Indexed keywords

TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST; BREAST RECONSTRUCTION; BREAST TUMOR; DNA METHYLATION; FAMILY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HEALTH; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; RACE; RISK FACTOR;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; BREAST; BREAST NEOPLASMS; CONTINENTAL POPULATION GROUPS; DNA METHYLATION; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEALTH; HUMANS; MAMMAPLASTY; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 77955132259     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00924.x     Document Type: Article

References (45)

1. Trichopoulos D, Adami HO, Ekbom A. Early life events and conditions and breast cancer risk: from epidemiology to etiology. Int J Cancer. 2008, 3:481-5.
2. Barba M, McCann SE, Nie J. Perinatal exposures and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control. 2006, 4:395-01.
3. Weiss HA, Potischman NA, Brinton LA. Prenatal and perinatal risk factors for breast cancer in young women. Epidemiology. 1997, 2:181-7.
4. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene. 2002, 35:5462-82.
5. Jacinto FV, Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis. 2007, 4:247-53.
6. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 4:683-92.
7. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006, 2:107-16.
8. Tao MH, Shields PG, Nie J. DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat. 2009, 114:559-68.
9. Holst CR, Nuovo GJ, Esteller M. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 2003, 7:1596-601.
10. Esteller M, Silva JM, Dominguez G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000, 7:564-9.
11. Bean GR, Ibarra DC, Goldenberg VK. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007, 1:50-6.
12. Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 2002, 5:197-01.
13. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005, 629-56.
14. Leu YW, Yan PS, Fan M. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res. 2004, 22:8184-92.
15. Nass SJ, Herman JG, Gabrielson E. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res. 2000, 16:4346-8.
16. Sirchia SM, Ferguson AT, Sironi E. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene. 2000, 12:1556-63.
17. Farias EF, Arapshian A, Bleiweiss IJ. Retinoic acid receptor alpha2 is a growth suppressor epigenetically silenced in MCF-7 human breast cancer cells. Cell Growth Differ. 2002, 8:335-41.
18. Alvarez S, az-Uriarte R, Osorio A. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res. 2005, 3:1146-53.
19. Fackler MJ, McVeigh M, Evron E. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer. 2003, 6:970-5.
20. Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochem Pharmacol. 2004, 6:1187-97.
21. Lewis CM, Cler LR, Bu DW. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res. 2005, 1:166-72.
22. Locke I, Kote-Jarai Z, Fackler MJ. Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls. Breast Cancer Res 2007, 1:R20.
23. Bianco T, Chenevix-Trench G, Walsh DC. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis. 2000, 2:147-51.
24. Esteller M, Corn PG, Baylin SB. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 8:3225-9.
25. Woodcock DM, Linsenmeyer ME, Doherty JP. DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours. Br J Cancer. 1999, 2:251-6.
26. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 1997, 16:3347-50.
27. Palmisano WA, Divine KK, Saccomanno G. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000, 21:5954-8.
28. Baldwin RL, Nemeth E, Tran H. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000, 19:5329-33.
29. Zochbauer-Muller S, Minna JD, Gazdar AF. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist. 2002, 5:451-7.
30. Tsou JA, Hagen JA, Carpenter CL. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene. 2002, 35:5450-61.
31. Romanov SR, Kozakiewicz BK, Holst CR. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature. 2001, 6820:633-7.
32. Bean GR, Bryson AD, Pilie PG. Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res. 2007, 22:6834-41.
33. Wong DJ, Foster SA, Galloway DA. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol. 1999, 8:5642-51.
34. Teixeira MR, Pandis N, Heim S. Cytogenetic clues to breast carcinogenesis. Genes Chromosomes Cancer. 2002, 1:1-16.
35. O'Hagan HM, Mohammad HP, Baylin SB. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet 2008, 4:e1000155.
36. Toyota M, Ohe-Toyota M, Ahuja N. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA. 2000, 2:710-5.
37. Cancer Facts and Figures. 2008, 9-11. http://www.cancer.org/docroot/stt/content/stt_1x_cancer_facts_and_figures_2008.asp, American Cancer Society, Available from
38. Field TS, Buist DS, Doubeni C. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr. 2005, 35:88-95.
39. Carey LA, Perou CM, Livasy CA. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 21:2492-502.
40. Mehrotra J, Ganpat MM, Kanaan Y. Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res. 2004, 6:2052-7.
41. Kusano AS, Trichopoulos D, Terry KL. A prospective study of breast size and premenopausal breast cancer incidence. Int J Cancer. 2006, 8:2031-4.
42. Boice JD, Persson I, Brinton LA. Breast cancer following breast reduction surgery in Sweden. Plast Reconstr Surg. 2000, 4:755-62.
43. Palmieri B, Benuzzi G, Costa A. Breast reduction and subsequent cancer: a prophylactic perspective. Breast. 2006, 4:476-81.
44. Brinton LA, Persson I, Boice JD. Breast cancer risk in relation to amount of tissue removed during breast reduction operations in Sweden. Cancer. 2001, 3:478-83.
45. Cancer Incidence, Mortality and Prevalence Worldwide. 2004, IARC